Lineage Cell Therapeutics Statistics
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.7719-0.0481 (-5.87%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Lineage Cell Therapeutics by the numbers
Lineage Cell Therapeutics has a market capitalization of $195.3 million based on 252.95M shares outstanding. With trailing EPS of $-0.09, Lineage Cell Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 20.8% below its 50-day average and 39.5% below its 200-day average.
Average daily trading volume is 1.64M shares, or about $1.3 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
LCTX valuation vs. peer median
| Metric | LCTX | Peer median | Difference |
|---|---|---|---|
| Market cap | $195.26M | $194.40M | +0% |
| Avg. volume | 1.64M | 775.98K | +112% |
Peer median across 8 companies: CABA, ARTV, IKT, IPSC, CGEN, ALLO, SCTX, PALI.
Valuation
- Market cap
- $195.26M
- Price / sales (latest FY)
- 13.41
- EPS (TTM)
- $-0.09
- Shares outstanding
- 252.95M
Price and trading
- Previous close
- 0.82
- Open
- 0.81
- Day range
- 0.77 – 0.8383
- 52-week range
- 0.77 – 1.99
- 52-week change
- -55.64%
- 50-day moving average
- 0.9748
- Beta
- —
- Volume
- 2.04M
- Average volume
- 1.64M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 12, 2026
Additional statistics
- Market Cap
- 195.26M
- Forward Pe
- -7.02
- Eps
- -0.09
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 1.99
- Week52 Low
- 0.77
- Avg Volume
- 1.64M
- Shares Outstanding
- 252.95M
- Ma50
- 0.97
- Ma200
- 1.28
- Earnings Date
- Nov 12, 2026
- Pct From52w High
- -61.21%
- Pct From52w Low
- 0.25%